Within-Subject Comparison of [11C]-( + )-PHNO and [11C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans

[1]  Mark Jenkinson,et al.  Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy , 2011, NeuroImage.

[2]  Alan A. Wilson,et al.  Isoflurane Anaesthesia Differentially Affects the Amphetamine Sensitivity of Agonist and Antagonist D2/D3 Positron Emission Tomography Radiotracers: Implications for In Vivo Imaging of Dopamine Release , 2011, Molecular Imaging and Biology.

[3]  John D. Beaver,et al.  Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist , 2010, Biological Psychiatry.

[4]  Diana Martinez,et al.  A Comparative Evaluation of the Dopamine D2/3 Agonist Radiotracer [11C](−)-N-Propyl-norapomorphine and Antagonist [11C]Raclopride to Measure Amphetamine-Induced Dopamine Release in the Human Striatum , 2010, Journal of Pharmacology and Experimental Therapeutics.

[5]  Jeih-San Liow,et al.  D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model , 2010, NeuroImage.

[6]  Mark Slifstein,et al.  Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers , 2010, Neuropsychopharmacology.

[7]  Mark Slifstein,et al.  In vivo quantification of regional dopamine‐D3 receptor binding potential of (+)‐PHNO: Studies in non‐human primates and transgenic mice , 2009, Synapse.

[8]  John D. Beaver,et al.  [11C]PHNO studies in rhesus monkey: In vivo affinity for D2 and D3 receptors and dosimetry , 2009 .

[9]  Christer Halldin,et al.  Dopamine D 2/3 Receptor Occupancy of Apomorphine in the Nonhuman Primate Brain—A Comparative PET Study With , 2022 .

[10]  Alan A. Wilson,et al.  First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study , 2008, Neuropsychopharmacology.

[11]  Alan A. Wilson,et al.  Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. , 2008, Nuclear medicine and biology.

[12]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  R. Narendran,et al.  Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]‐(+)‐PHNO is a D3 receptor preferring agonist in vivo , 2006, Synapse.

[14]  Alain Dagher,et al.  Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. , 2006, Archives of general psychiatry.

[15]  Dean F. Wong,et al.  Sex Differences in Striatal Dopamine Release in Healthy Adults , 2006, Biological Psychiatry.

[16]  Sylvain Houle,et al.  Binding characteristics and sensitivity to endogenous dopamine of [11C]‐(+)‐PHNO, a new agonist radiotracer for imaging the high‐affinity state of D2 receptors in vivo using positron emission tomography , 2006, Journal of neurochemistry.

[17]  Sylvain Houle,et al.  Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. , 2005, Journal of medicinal chemistry.

[18]  James Robert Brašić,et al.  Relationships Among Ventral Striatal Dopamine Release, Cortisol Secretion, and Subjective Responses to Amphetamine , 2005, Neuropsychopharmacology.

[19]  P. Bonaventure,et al.  Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study , 1996, The Histochemical Journal.

[20]  B. Långström,et al.  Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography , 2005, Journal of Neural Transmission.

[21]  Mark Slifstein,et al.  In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride , 2004, Synapse.

[22]  Ella Hirani,et al.  Temporal characterisation of amphetamine‐induced dopamine release assessed with [11C]raclopride in anaesthetised rodents , 2004, Synapse.

[23]  A. Dagher,et al.  Amphetamine-Induced Increases in Extracellular Dopamine, Drug Wanting, and Novelty Seeking: A PET/[11C]Raclopride Study in Healthy Men , 2002, Neuropsychopharmacology.

[24]  D. Kupfer,et al.  Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria , 2001, Biological Psychiatry.

[25]  M. Laruelle.  Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Paul E Kinahan,et al.  PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum , 1999, Neuropsychopharmacology.

[27]  M Laruelle,et al.  Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.

[28]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[29]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[31]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[32]  Anita B. Roberts,et al.  THE ANTERIOR PITUITARY , 1995 .

[33]  J. Leysen,et al.  Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. , 1992, European journal of pharmacology.

[34]  M. Martres,et al.  Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.

[35]  G. Damsma,et al.  Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  P. Kalivas,et al.  Somatodendritic release of endogenous dopamine: in vivo dialysis in the A10 dopamine region , 1989, Neuroscience Letters.

[37]  T. Högberg,et al.  Synthesis of [methoxy-3H]- and [methoxy-11C]- labelled raclopride. Specific dopamine-D2 receptor ligands , 1987 .

[38]  D. Sibley,et al.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.

[39]  Pharmacology I human , 1981, PAIN.

[40]  S. Snyder,et al.  Dopamine receptor binding regulated by guanine nucleotides. , 1979, Molecular pharmacology.

[41]  P. Molinoff,et al.  Effect of guanine nucleotides on striatal dopamine receptors , 1978, Nature.

[42]  I. Creese,et al.  Dopamine receptor binding: specificity, localization and regulation by ions and guanyl nucleotides. , 1978, Life sciences.